ELI LILLY & Co.
- LLY · NYSE
- Pharmaceutical Preparations
- Indianapolis, IN
- 50,000 employees
- CIK 0000059478
Updated from SEC filings through
Top things to know
Executives
- David A. Ricks Lilly chair and CEO 8-K, 2026-10-29
- David Ricks Chair, President, and Chief Executive Officer (CEO) 10-K, 2026-02-12
-
Lucas Montarce EVP & CFO 4, 2026-02-18 -
Adrienne S. Brown EVP, President LLY Imm 3/A, 2026-09-04 -
Eric Dozier EVP, Chief People Officer 4, 2026-09-04 -
Patrik Jonsson EVP & President, LLY Int'l 4, 2026-08-18
What leadership is saying
“Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook”
Earnings press release (8-K Ex. 99.1), filed October 29, 2026
ELI LILLY & Co is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Indianapolis, IN. It trades as LLY on NYSE. Revenue was $65.2B in the fiscal year ending December 31, 2025, +44.7% from the year before. It reported about 50,000 employees. David A. Ricks is Lilly chair and CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65.2B 10-K, 2026-02-12 | $45.0B 10-K, 2026-02-12 | $34.1B 10-K, 2026-02-12 | $28.5B 10-K, 2025-02-19 | $28.3B 10-K, 2024-02-21 |
| Operating income | Not on file | Not on file | Not on file | Not on file | Not on file |
| SG&A | $11.1B 10-K, 2026-02-12 | $8.6B 10-K, 2026-02-12 | $7.4B 10-K, 2026-02-12 | $6.4B 10-K, 2025-02-19 | $6.4B 10-K, 2024-02-21 |
| Net income | $20.6B 10-K, 2026-02-12 | $10.6B 10-K, 2026-02-12 | $5.2B 10-K, 2026-02-12 | $6.2B 10-K, 2025-02-19 | $5.6B 10-K, 2024-02-21 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| David A. Ricks | Lilly chair and CEO | 8-K, 2026-10-29 |
| David Ricks | Chair, President, and Chief Executive Officer (CEO) | 10-K, 2026-02-12 |
| Lucas Montarce Executive Vice President and Chief Financial Officer | EVP & CFO | 4, 2026-02-18 |
| Adrienne S. Brown | EVP, President LLY Imm | 3/A, 2026-09-04 |
| Eric Dozier Executive Vice President, Chief People Officer at Eli Lilly and Company | EVP, Chief People Officer | 4, 2026-09-04 |
| Patrik Jonsson President, Lilly International at Eli Lilly and Company | EVP & President, LLY Int'l | 4, 2026-08-18 |
| Kenneth L. Custer President of Lilly Cardiometabolic Health | EVP & President, Card Met Hlth | 4, 2026-02-18 |
| Adrienne Brown | Executive Vice President and President, Lilly Immunology | 10-K, 2026-02-12 |
| Carole Ho Executive Vice President and President, Lilly Neuroscience, Eli Lilly and Company | Executive Vice President and President, Lilly Neuroscience | 10-K, 2026-02-12 |
| Donald Zakrowski Senior Vice President, Chief Accounting Officer at Eli Lilly | Senior Vice President, Finance, and Chief Accounting Officer | 10-K, 2026-02-12 |
 Jacob Van Naarden President, Loxo@Lilly, Eli Lilly and Company | Executive Vice President, President, Lilly Oncology and Head of Corporate Business Development | 10-K, 2026-02-12 |
| Kenneth Custer, Ph.D. | Executive Vice President and President, Lilly Cardiometabolic Health | 10-K, 2026-02-12 |
 Melissa Seymour EVP and Chief Quality Officer at Eli Lilly | EVP, Global Quality | 4, 2026-09-11 |
 Edgardo Hernandez President, Global Manufacturing at Eli Lilly and Company | EVP & Pres., Mfg. Operations | 4, 2026-09-04 |
| Donald A. Zakrowski | SVP, Finance, & CAO | 4, 2026-08-11 |
 Anat Hakim Executive Vice President, General Counsel and Secretary at Eli Lilly and Company | EVP, GC & Secretary | 4, 2026-08-10 |
What ELI LILLY & Co does
Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 940.7 million (as of October 26, 2026) | 10-Q, October 29, 2026 |
|---|---|---|
| Public float | $808B (as of June 30, 2025) | 10-K, February 12, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, October 29, 2026 |
| Latest proxy statement | Meeting March 20, 2026 (filed March 20, 2026) | DEF 14A, March 20, 2026 |
| Auditor | Ernst & Young LLP (Indianapolis, Indiana) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 2, 2026 | Anat Hakim EVP, GC & Secretary | Sale | 5,000 | $7.0M | Form 4, November 3, 2026 |
| August 17, 2026 | Patrik Jonsson EVP & President, LLY Int'l | Sale | 6,500 | $7.6M | Form 4, August 18, 2026 |
| August 10, 2026 | Donald A. Zakrowski SVP, Finance, & CAO | Sale | 2,000 | $2.4M | Form 4, August 11, 2026 |
| August 7, 2026 | Anat Hakim EVP, GC & Secretary | Sale | 5,000 | $6.0M | Form 4, August 10, 2026 |
| June 10, 2026 | Ilya Yuffa EVP&Pres, LLY USA&Global Capab | Sale | 2,500 | $2.9M | Form 4, June 11, 2026 |
| November 13, 2025 | Donald A. Zakrowski SVP, Finance, & CAO | Sale | 1,000 | $1.0M | Form 4, November 13, 2025 |
| August 28, 2025 | Donald A. Zakrowski SVP, Finance, & CAO | Sale | 1,000 | $735K | Form 4, August 28, 2025 |
| August 15, 2025 | Lucas Montarce EVP & CFO | Buy | 715 | $495K | Form 4, August 15, 2025 |
Recent 8-K events
- 8-K filed 2026-10-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-20
- Item 8.01 Other events
- 8-K filed 2026-05-07
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-21
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2025-10-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-08-20
- Item 8.01 Other events
- 8-K filed 2025-08-07
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about ELI LILLY & Co
- What does ELI LILLY & Co do?
- ELI LILLY & Co is classified by the SEC as Pharmaceutical Preparations (SIC 2834). It is based in Indianapolis, IN.
- What is ELI LILLY & Co's revenue?
- $65.2B for the fiscal year ending December 31, 2025, from its 10-K filed February 12, 2026.
- Is ELI LILLY & Co profitable?
- ELI LILLY & Co reported net income of $20.6B for the fiscal year ending December 31, 2025.
- How many employees does ELI LILLY & Co have?
- About 50,000 as of February 12, 2026, as stated in its annual report.
- Who is the CEO of ELI LILLY & Co?
- David A. Ricks, Lilly chair and CEO, as named in a 8-K filed October 29, 2026.
- Who is the CFO of ELI LILLY & Co?
- Lucas Montarce, EVP & CFO, as named in a 4 filed February 18, 2026.
- Where is ELI LILLY & Co headquartered?
- Indianapolis, IN.
- What is ELI LILLY & Co's stock ticker?
- LLY on NYSE.
- What industry is ELI LILLY & Co in?
- Pharmaceutical Preparations, SIC code 2834.
- What is ELI LILLY & Co's website?
- lilly.com. Investor relations: https://investor.lilly.com/.
- When does ELI LILLY & Co report earnings next?
- February 3, 2027. Source: estimate_8k_pattern.
- Is ELI LILLY & Co a public company?
- Yes. ELI LILLY & Co files with the SEC under CIK 0000059478 and trades as LLY.
- Who audits ELI LILLY & Co?
- Ernst & Young LLP, Indianapolis, Indiana, as named in its latest annual report (10-K).
- How many shares of ELI LILLY & Co are outstanding?
- 940.7 million shares as of October 26, 2026, from its 10-Q filed October 29, 2026.
- What is ELI LILLY & Co's public float?
- $808B as of June 30, 2025, as reported on the cover of its 10-K filed February 12, 2026.
- How many business segments does ELI LILLY & Co report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed October 29, 2026.
- When is ELI LILLY & Co's annual shareholder meeting?
- March 20, 2026, per its proxy statement (DEF 14A) filed March 20, 2026.
- Have ELI LILLY & Co insiders traded stock recently?
- Since August 8, 2025, officers and directors reported 8 open-market sales worth about $28.4M and 8 purchases worth about $4.5M on Forms 4 and 5. The most recent: Anat Hakim (EVP, GC & Secretary) sold 5,000 shares on November 2, 2026.